Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Johnson Controls International PLC (JCI) Price & Performance

Enveric Biosciences IncTrade
Johnson Controls International PLCTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Johnson Controls International PLC — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Johnson Controls International PLC trades at $155.47 (market cap $91.29B). The key difference: Johnson Controls International PLC is far larger — about 14724.2× Enveric Biosciences Inc's market cap, and Johnson Controls International PLC pays a 1.06% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

ENVBJCI
Market Cap
$6.20M$91.29B
Sector
HealthIndustrials
52-Week High
$17.40$154.76
52-Week Low
$1.27$103.52
Enterprise Value
$1.30M$100.12B
Dividend Yield
1.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Johnson Controls International PLC

Johnson Controls International (JCI) trades at $152.21, down 1.51% on the day, but maintains a bullish technical outlook with strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with EPS of $1.42 versus $1.30 expected, and raised full-year guidance. Fundamentals show solid revenue growth and expanding net income margins, though valuation multiples like a P/E of 42.88 appear elevated. Recent news highlights strong demand for its thermal management systems, particularly in data centers.

JCI's outlook is positive, driven by operational strength and strategic positioning in high-growth markets like AI infrastructure. Investment opportunities include continued earnings beats and market share gains in energy efficiency solutions. Key risks involve high valuation sensitivity, competitive pressures, and macroeconomic factors affecting construction and industrial spending. The consensus price target of $168.25 suggests ~10% upside from current levels.

Returns comparison

Trailing returns across standard periods

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Johnson Controls International PLC

Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.

Read more on JCI